Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers

D. Hoskovec, J. Varga, E. Konečná, F. Antos,

. 2012 ; 27 (6) : 410-6.

Jazyk angličtina Země Brazílie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc13024421

PURPOSE: Tumor markers are substances found in blood and other biological fluids if tumor is present in the body. They can be produced by tumor itself or can be results of cancer - body relation. They may be used in the follow-up of cancer patients to identify tumor recurrence. Pre-treatment levels have prognostic tool and could signalize persistence of minimal residual disease despite radical surgery. METHODS: We operated on 52 patients with upper GI malignancy (32 with gastric cancer and 20 with pancreatic cancer). Blood samples were taken before surgery and peritoneal samples immediately after laparotomy before any manipulation with tumor. All samples were examined by standard biochemical technique and the level was compared with a stage of the disease. RESULTS: Patients suffering from gastric carcinoma of stage I and II had higher level of both markers in sera then in the peritoneal cavity, however most of them were within physiological range. Patients in stage III and IV had average marker levels in the peritoneal cavity higher than in sera. Number of positive findings was increasing according to the stage of the disease. The peritoneal levels of both markers varied extremely in higher stages. In patients suffering from pancreatic carcinoma the CEA levels both in sera and peritoneal cavity were parallel but peritoneal levels were slightly higher in stages III and IV. Ca 19 - 9 was more sensitive for pancreatic cancer. The percentage of positive findings was higher in sera but the level of Ca 19 - 9 was higher in the peritoneal cavity. The number of positive findings again correlated with the stage of the disease. CONCLUSIONS: Levels of tumor markers in sera could signalize inoperability of tumor (Ca 19 - 9 in cases of pancreatic carcinoma); peritoneal levels could predict R1 resection especially in gastric cancer patients and risk of early peritoneal recurrence of the disease. Difference between the levels in the peritoneum and sera may signalize the route of dissemination (hematogenous and intraperitoneal).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13024421
003      
CZ-PrNML
005      
20130704093805.0
007      
ta
008      
130703s2012 bl f 000 0|eng||
009      
AR
024    7_
$a 10.1590/s0102-86502012000600009 $2 doi
035    __
$a (PubMed)22666759
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a bl
100    1_
$a Hoskovec, David $u Charles University Prague, Czech Republic. david.hoskovec@vfn.cz
245    10
$a Levels of CEA and Ca 19 - 9 in the sera and peritoneal cavity in patients with gastric and pancreatic cancers / $c D. Hoskovec, J. Varga, E. Konečná, F. Antos,
520    9_
$a PURPOSE: Tumor markers are substances found in blood and other biological fluids if tumor is present in the body. They can be produced by tumor itself or can be results of cancer - body relation. They may be used in the follow-up of cancer patients to identify tumor recurrence. Pre-treatment levels have prognostic tool and could signalize persistence of minimal residual disease despite radical surgery. METHODS: We operated on 52 patients with upper GI malignancy (32 with gastric cancer and 20 with pancreatic cancer). Blood samples were taken before surgery and peritoneal samples immediately after laparotomy before any manipulation with tumor. All samples were examined by standard biochemical technique and the level was compared with a stage of the disease. RESULTS: Patients suffering from gastric carcinoma of stage I and II had higher level of both markers in sera then in the peritoneal cavity, however most of them were within physiological range. Patients in stage III and IV had average marker levels in the peritoneal cavity higher than in sera. Number of positive findings was increasing according to the stage of the disease. The peritoneal levels of both markers varied extremely in higher stages. In patients suffering from pancreatic carcinoma the CEA levels both in sera and peritoneal cavity were parallel but peritoneal levels were slightly higher in stages III and IV. Ca 19 - 9 was more sensitive for pancreatic cancer. The percentage of positive findings was higher in sera but the level of Ca 19 - 9 was higher in the peritoneal cavity. The number of positive findings again correlated with the stage of the disease. CONCLUSIONS: Levels of tumor markers in sera could signalize inoperability of tumor (Ca 19 - 9 in cases of pancreatic carcinoma); peritoneal levels could predict R1 resection especially in gastric cancer patients and risk of early peritoneal recurrence of the disease. Difference between the levels in the peritoneum and sera may signalize the route of dissemination (hematogenous and intraperitoneal).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a antigen CA-19-9 $x analýza $x krev $7 D018395
650    _2
$a karcinoembryonální antigen $x analýza $x krev $7 D002272
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a nádory slinivky břišní $x krev $x chemie $x patologie $7 D010190
650    _2
$a peritoneální dutina $7 D010529
650    _2
$a peritoneální výplach $7 D010533
650    _2
$a peritoneální nádory $x krev $x chemie $x sekundární $7 D010534
650    _2
$a nádory žaludku $x krev $x chemie $7 D013274
655    _2
$a časopisecké články $7 D016428
700    1_
$a Varga, Jozef $u -
700    1_
$a Konečná, Ellen $u -
700    1_
$a Antos, Frantisek $u - $7 gn_A_00007526
773    0_
$w MED00172282 $t Acta cirúrgica brasileira / Sociedade Brasileira para Desenvolvimento Pesquisa em Cirurgia $x 1678-2674 $g Roč. 27, č. 6 (2012), s. 410-6
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22666759 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130703 $b ABA008
991    __
$a 20130704094223 $b ABA008
999    __
$a ok $b bmc $g 988101 $s 822801
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 27 $c 6 $d 410-6 $i 1678-2674 $m Acta Cirúrgica Brasileira $n Acta Cir Bras $x MED00172282
LZP    __
$a Pubmed-20130703

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...